UV1

Phase 2Biologic

UUltimovacs ASA

UV1 is one of 202 biologic programs targeting Metastatic Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

201

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

UV1

UUltimovacs ASA

Phase 2

1 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Remeron

OOrganon and Co

Preclinical

1 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05344209

Clinical

Trials by Indication[1]

Melanoma2 trials

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Completed·UUltimovacs ASA·Phase 1/2·NCT02275416·12 enrolled

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Completed·UUltimovacs ASA·Phase 2·NCT04382664·156 enrolled

Prostate Cancer1 trial

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Completed·UUltimovacs ASA·Phase 1/2·NCT01784913·22 enrolled

Small Cell Lung Cancer1 trial

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

Completed·UUltimovacs ASA·Phase 1/2·NCT01789099·18 enrolled

Non-Small Cell Lung Cancer1 trial

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Recruiting·VVestre Viken Hospital Trust·Phase 2·NCT05344209·138 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Unknown status·MMartin-Luther-Universität Halle-Wittenberg·Phase 2·NCT05075122·75 enrolled

1 more indication

Metastatic Melanoma1 trial

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Completed·UUltimovacs ASA·Phase 1·NCT03538314·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for UV1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UV1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UV1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ultimovacs ASA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUltimovacs ASA

UV1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Melanoma2 trials

Prostate Cancer1 trial

Small Cell Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News